1. Navigate to /scrip
  2. Navigate to /scrip/covid-19

Coronavirus Update: Pfizer/BioNTech Vaccine Shows Six-Month, Variant Protection

 
• By Scrip Team
  
Generate a summary of this article
Listen to this article
Beta

The companies still plan to develop a variant-specific version, while J&J said it anticipates meeting vaccine supply goals despite a manufacturing mix-up.

COVID-19 vaccine
Pfizer/BioNTech announced six-month and variant data for BNT162b2, while J&J said it anticipates meeting its supply goals • Source: Shutterstock

Pfizer Inc. and BioNTech SE continue to roll out additional data supporting their mRNA vaccine against SARS-CoV-2 with updated data from the Phase III study of BNT162b2 showing similar levels of protection up to six months later among people who received both doses. The updated data also provide more evidence of efficacy against the B.1.351 South African variant strain.

The findings of the latest analysis bolsters recent data showing BNT162b2’s efficacy and an early advantage over competitors, although similar...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain

 
• By Alaric DeArment

Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.

Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy

 
• By Alaric DeArment

The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

 
• By Elizabeth Cairns

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.    

Stock Watch: Thoroughly Moderna Missteps

 
• By Andy Smith

When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains